Adjuvant radiotherapy shows benefit in selected stage I uterine sarcoma: A risk scoring system based on a population analysis

Background The potential therapeutic benefit of adjuvant radiotherapy for patients with stage I uterine sarcoma has not been clear. In this study, we aimed to develop a risk scoring model to select the subgroup of patients with stage I uterine sarcoma who might benefit from adjuvant radiotherapy. Me...

Full description

Saved in:
Bibliographic Details
Published in:Cancer medicine (Malden, MA) MA), 2022-07, Vol.11 (14), p.2846-2854
Main Authors: Huang, Yun‐xia, Lin, Yan‐zong, Li, Yi‐min, Chu, Ke‐xin, Zhou, Yu‐fei, Lin, Li‐mei, Zhou, Rui, Zhang, Zong‐kai, Lin, Qin
Format: Article
Language:English
Subjects:
adjuvant radiotherapy
Age
Chemotherapy
Epidemiology
Histology
Hysterectomy
Medical prognosis
Multivariate analysis
Oophorectomy
Patients
Population studies
prognosis
Radiation therapy
Risk factors
Sarcoma
SEER
stage I uterine sarcoma
Surgery
Survival
Tumors
Uterine cancer
Uterus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The potential therapeutic benefit of adjuvant radiotherapy for patients with stage I uterine sarcoma has not been clear. In this study, we aimed to develop a risk scoring model to select the subgroup of patients with stage I uterine sarcoma who might benefit from adjuvant radiotherapy. Methods Patients with stage I uterine sarcoma from the Surveillance, Epidemiology, and End Results program from 2010 to 2014 were retrospectively included in this analysis. Cox proportional hazards models were performed to identify risk factors. Results A total of 947 stage I uterine sarcoma patients were included. The 5‐year disease‐specific survival (DSS) of the overall cohort was 75.81%. Multivariate analysis identified stage (p = 0.013), tumor grade (p 
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.4643